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Abstract: Alzheimer’s disease is a type of dementia characterized by problems with short-term mem-
ory, cognition, and difficulties with activities of daily living. It is a progressive, neurodegenerative
disorder. The complement system is an ancient part of the innate immune system and comprises of
more than thirty serum and membrane-bound proteins. This system has three different activating
pathways and culminates into the formation of a membrane attack complex that ultimately causes tar-
get cell lysis (usually pathogens) The complement system is involved in several important functions
in the central nervous system (CNS) that include neurogenesis, synaptic pruning, apoptosis, and
neuronal plasticity. Here, we discuss how the complement system is involved in the effective func-
tioning of CNS, while also contributing to chronic neuroinflammation leading to neurodegenerative
disorders such as Alzheimer’s disease. We also discuss potential targets in the complement system
for stopping its harmful effects via neuroinflammation and provide perspective for the direction of
future research in this field.
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1. Introduction
Alzheimer’s disease (AD) is the most frequent form of dementia in the elderly and
accounts for approximately 60–70% of all cases [1,2]. AD is the most prevalent neurode-
generative disorder in the elderly which results in a slow and progressive decline in both
memory and executive cognitive functions [2,3]. Some of the core clinical features are
progressive memory loss, apraxia (inability to perform movements and gestures), agnosia
(inability to recognise and identify people, objects, and sounds), language decline, and be-
havioural changes such as the loss of executive brain functions [2]. Unfortunately, there are
still no treatments available to stop the pathophysiological processes or even progression
of AD [2,3].
1.1. Epidemiology of Alzheimer’s Disease
According to the World Health Organization (WHO), there are approximately 50 mil-
lion people worldwide who suffer from dementia; it is estimated that 30 million people
have AD [1]. There are approximately 10 million new cases of dementia diagnosed each
year across the globe, approximately 6 million cases are of AD [1]. One of the major risk
factors for dementia is age; with increasing life expectancy, cases of dementia are only
predicted to rise further. There is a higher prevalence in females, probably due to higher
life expectancy compared with males [4,5].
1.2. Risk factors of Alzheimer’s Disease
AD is a multifactorial disease; it is considered to be caused by an interplay of multiple
risk factors such as lifestyle, environmental, and genetic factors [6]. These factors interact
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with one another to cause the onset or alter the progression of sporadic late onset AD
(LOAD), which forms the majority of cases in individuals over the age of 60–65 years [7].
Other types of rare AD cases are known as young onset familial AD, which occurs in
individuals before the age of 60, particularly between 30 and 60 years of age [6,7]. These
young onset familial AD cases generally have multiple individuals in one generation who
have AD; these cases are predominantly linked to mutations in autosomal dominant genes
such as the amyloid-β precursor protein (APP), Presenilin 1 (PS1), or Presenilin 1 (PS2)
genes [7,8].
Cardiovascular disease can combine with potentially modifiable lifestyle related risk
factors and influence the pathogenesis of AD [7–9]. A recent study identified 12 modifiable
risk factors: hypertension, obesity, diabetes, smoking, depression, physical inactivity, hear-
ing impairment, lack of education, low social contact, excessive alcohol consumption, air
pollution, and traumatic brain injury (TBI) [8]. Meta-analyses of these risk factors showed
that they may account for approximately 40% of dementia cases across the world [7,8].
Cardiovascular disease can lead to vascular damage of the brain, which increases the
risk of macro- and microvascular damage and subsequent brain atrophy [7,8]. Further
insults by modifiable risk factors such as diabetes and metabolic syndrome can result in
atherosclerosis, brain infarctions, while patients with obesity and insulin-resistance show
dysregulation of the complement system associated with chronic low-level inflammation
of adipose tissue [7,8,10].
Genetic studies have identified cardiovascular disease associated loci which increase
the risk of LOAD [9]. The most prominent gene associated with the strongest impact
on LOAD is the apolipoprotein ε4 (APOE-ε4) gene which is involved in cholesterol
metabolism [9,11]. APOE-ε4 heterozygotes have three times increased risk of LOAD, and
homozygotes have a 15 times higher risk [7]. Genome wide association studies (GWAS)
have identified multiple single nucleotide polymorphisms (SNPs) which can increase the
risk of AD including the ATP-binding cassette sub-family A member 7 (ABCA7) and clus-
terin (CLU) that are involved in lipid transport [9,12]. Other low risk loci identified by
GWAS include triggering receptors expressed on myeloid cells 2 (TREM2), complement
receptor type 1 (CR1), bridging integrator 1 (BIN1), cathepsin D (CTSD), and CD33 [6].
1.3. The Pathophysiological Changes in Alzheimer’s Disease
AD starts decades before any clinical symptoms manifest [13]. In this preclinical
phase, individuals are often clinically asymptomatic but show evidence of AD neuropathol-
ogy [13]. This preclinical phase can last for decades until later the individual goes through
the clinical phases where symptoms of AD begin to manifest and progress [13].
Our current understanding of AD includes two key neuropathological hallmarks—
amyloid plaques and neurofibrillary tangles (NFTs) [13]. Amyloid plaques are composed
of extracellular deposits of amyloid beta (Aβ) peptides [13]. The Aβ plaques can be diffuse
amorphous nonfibrillar Aβ aggregates and/or neuritic plaques. Neuritic plaques are
composed of Aβ arranged into β-pleated sheets [13]. Intraneuronal NFTs are composed
of aggregates of paired helical filaments (PHFs) of abnormally hyperphosphorylated tau
(p-tau) protein [14]. P-tau then aggregates within the neuron leading to the formation of
NFTs [14].
It is now clear that neuroinflammation plays a significant role in AD pathophysiology.
Studies have shown the presence of reactive glial cells such as microglia and astrocytes,
and inflammatory mediators including of the complement system around Aβ plaques.
This indicates a significant role for neuroinflammation in AD progression and subsequent
neurodegeneration [15,16].
1.3.1. Aβ and the Amyloid Hypotheses
Since the amyloid hypothesis proposed by Hardy and Allsop et al. (1991), Aβ has
been thought to be the main causative factor for AD [17], who identified a mutation in the
amyloid precursor protein (APP) gene on chromosome 21, and suggested that APP mis-
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metabolism and Aβ deposition were key drivers in the pathological cascade of AD [17,18].
The hypothesis suggests that misfolding and deposition of Aβ results in the formation of
extracellular Aβ plaques, this leads to tau becoming abnormally hyperphosphorylated
becomimg p-tau, leading to the eventual formation of NFTs, and then neuronal death [17].
The hypothesis was further supported by the demonstration of the presence of Aβ in APP
mutant transgenic mice [19].
The APP is a 695 amino acid-long glycoprotein which can be cleaved by three path-
ways via α-, β-, γ-, and η-secretases resulting in the production of C-terminal fragments
(CTF) [20] (Figure 1). The non-amyloidogenic pathway is where APP is hydrolysed by
α-secretase which produces products such as CTF-α, which is bound to the cell membrane,
and APP-α (sAPPα) which has a soluble ectodomain [20,21]. Both CTF-α and sAPPα are
thought to have a neurotrophic and neuroprotective role [20,21]. Following this, CTF-α is
cleaved inside the membrane by γ-secretase allowing the release of a peptide, known as
P3 [20,21]. P3 is a soluble peptide which does not tend to aggregate unlike Aβ [21]. The
non-amyloidogenic pathway does not produce Aβ peptides [18,20] (Figure 1).
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the Aβ1-40 isoform, but Aβ1-42 peptides are also present [15]. Any excess Aβ production
is cleared by activating glial cells and the complement system via phagocytosis [18].
Failure to clear Aβ1-42 peptides by the immune system due to the chronic neuroin-
flammation results in impaired microglial mediated Aβ clearance. This leads to an increase
in concentration and aggregation of Aβ1-42 peptides which causes neurotoxic effects such
as the release of proinflammatory cytokines and complement proteins, leading to microglia-
mediated neuronal death and synaptic destruction [18]. In AD, metal ion homeostasis is
disrupted which results in elevated levels of trace metal ions such as copper [23]. Copper is
also seen within Aβ plaques [23]. Interestingly, in a recent study, a correlation was observed
between plasma Cu2+ levels and complement components such as C3 and C4 (see below
for further details on complement systems and neuroinflammation). Copper is a metal ion
with redox properties and the copper (Cu2+) ions within Aβ plaques can produce hydrogen
peroxide and reactive oxygen species (ROS) via biological reducing agents such as ascorbic
acid, dopamine, and cholesterol [23,24]. ROS can cause dendritic and axonal atrophy
leading to neuronal dysfunction; this is of importance in key areas of the brain such as the
hippocampus [18,25,26]. The neurotoxic Aβ1-42 peptides are thought to be the key steps in
the pathological drive leading to AD [18,25]. It is thought that aggregation of Aβ peptides
begins in vivo decades before any clinical symptoms manifest [18,25]. These peptides act
on several receptors such as N-methyl-D-aspartate (NMDA) and α7-nicotinic acetylcholine
(α7-nACh) which causes the inhibition of long-term potentiation (LTP) in brain regions
such as the hippocampus and enhances long-term depression (LTD) [27]. Inhibition of LTP
can result in the shrinkage of dendritic spines and their gradual loss [25]. This leads to the
dysfunction of synapses and has a direct impact on learning and memory [18,25]. Aβ1-42
peptides also induce hyperphosphorylation of tau, further supporting the idea that that
Aβ can drive tau pathology [13,28].
1.3.2. Tau, Neurofibrillary Tangles and the Tau Propagation Hypothesis
The tau protein is normally found in neuronal axons in the brain and belongs to a
family of microtubule-associated proteins [18]. The main function of tau is to stabilise
microtubules that allows axonal transport, maintenance of synaptic structures and function,
and signaling between neurons [18]. Tau is produced by the alternative splicing of exons
2, 3 and 10 of the Microtubule-Associated Protein Tau (MAPT) gene which can produce
six tau isoforms [18,29]. These isoforms contain several microtubule binding carboxyl
terminals with repeats of either three or four arginine residues, which is to prevent tau from
aggregating [18,29]. Tau is known to be a phosphoprotein which can be phosphorylated
and dephosphorylated by protein kinases and phosphatases, respectively [18,29]. Tau has
a few phosphorylation sites. It has been shown that Aβ1-42 can activate glycogen synthase
kinase 3β (GSK3β), also formerly known as Tau protein kinase 1 (TPK1), which leads to the
abnormal hyperphosphorylation of tau and formation of p-tau, which can polymerise and
leads to the formation of PHFs and eventually NFTs; these processes further exacerbate
AD pathology [28,30]. NFTs are neurotoxic as they disrupt microtubule function and cause
subsequent impairment in axonal transport leading to synapse and neuronal damage and
eventual neurodegeneration [13].
The tau propagation hypothesis was first proposed in 2009 by Frost et al. [31], which
suggests that the progression of cognitive impairment in AD is linked to the spreading
of tau pathology in the brain [18]. It is thought that p-tau can more easily propagate
in a prion-like manner from one area of the brain to other areas; thus, spreading tau
pathology in the brain which leads to the activation of glial cells, neuroinflammation and
neurodegeneration [18,31]. This was supported by animal studies where brain extracts
from P301s tau transgenic mice were injected into the brains of ALZ17 mice that only
normally develop tau pathology late in life; it was found that these mice developed tau
pathology much quicker than their respective wildtype (WT) mice [18,32].
It is established now that Aβ is a strong driver for AD pathology. However, Aβ
alone may not be enough to impact on cognition but it can also drive the downstream
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pathology such as the eventual formation of p-tau and formation of NFTs which can affect
cognition [13].
1.3.3. Role of Neuroinflammation in AD
Neuroinflammation can be defined as an inflammatory response within the central
nervous system (CNS) in response to infection, trauma, and even neurodegenerative
diseases [16]. Neuroinflammation is mediated by the activation of glial cells such as
astrocytes and microglia, and the production of cytokines, chemokines, ROSs, and the
activation of the complement system [16]. Some pro-inflammatory cytokines include IL-1β,
IL-6, and tumour necrosis factor alpha (TNFα), and some chemokines include C-C motif
chemokine ligand 2 (CCL2), CCL5, and CXCL1 (C-X-C motif chemokine ligand 1) [16].
These inflammatory mediators are produced by the innate immune cells of the brain-
astrocytes and microglia [16]. However, it is important to note that these inflammatory
mediators can also be recruited from other parts of the body if there is a disruption in the
blood-brain-barrier (BBB) due to trauma or ageing resulting in the loss of its mechanical
integrity at the later stages of life [16].
The release of the pro-inflammatory mediators by innate immune cells can result in
the dysfunction of synapses, inhibition of neurogenesis and neuronal death; these features
are also seen in AD [16,33,34]. Anti-inflammatory cytokines such as IL-4, IL-9, IL-10, IL-11,
and transforming growth factor (TGF)-β1 are also produced during neuroinflammatory
events to potentially maintain a homeostatic balance to prevent excessive neuroinflam-
mation [16,35,36]. It is now evident that inflammatory mechanisms play a role in the
pathophysiology of AD [16,35,36]. It is understood that the effects of neuroinflammation
are neuroprotective only when it is low-level or present for a short time [3]. Neuroprotec-
tive benefits include immune surveillance by glial cells, thereby protecting from infections,
synaptic pruning which helps in improving cell-to-cell transmission, the remyelination
process, and the production of neutrophin that helps in neuronal growth [37]. However,
chronic neuroinflammation can occur when the neuroprotective mechanisms become over-
whelmed by Aβ and NFTs that make microglia and astrocytes more hyperactive which can
exacerbate AD pathology [37].
The deposition of Aβ is a key neuropathological hallmark and is a key initiating event
in the pathophysiology of AD [13]. The formation of Aβ plaques in the hippocampus is
of key importance as it is involved in short-term memory processing; the recruitment of
neurotoxic Aβ peptides results in disruption in homeostasis, synaptic dysfunction and
astrocyte and microglia hyperactivation [13,15,16]. Further insults by Aβ and a failure
of clearance can result in an increase in Aβ1-42 peptides which also have the ability to
bind to α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and
calcium ion (Ca2+) channels, leading to an increase in intracellular Ca2+ which over time
leads to chronic neuroinflammation and production of ROS and complement proteins via
microglia [13,15,16].
2. Role of the Complement System in CNS
The complement system is an essential component of the innate immune system and
acts as a bridge between innate and adaptive immunity [38]. It was first discovered by Jules
Bordet in 1896 and described as a heat-labile component of serum which “complemented”
antibodies [39]. The complement system comprises of over 40 proteins including control
proteins and cell surface receptors all of which are integral to the innate immune system,
allowing it to rapidly recognise and clear pathogens, and maintain homeostasis by clearing
apoptotic and necrotic cells and debris [16,40].
The complement proteins are used in a hierarchy of sequential proteolytic cascades
which are activated when a foreign pathogen, non-self ligand or altered host cells are recog-
nised [39]. The complement can induce an inflammatory response by pro-inflammatory
mediators (anaphylatoxins) and “tag” pathogens through a process known as opsonization
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for phagocytosis by antigen presenting cells (APCs), and target pathogens for lysis via the
formation of the membrane attack complex (MAC) [39].
The complement system also has a role in the CNS, which was once thought to be an
immune privileged system due to the BBB. Some of the roles of the complement system
in the CNS include synapse elimination during early development, synaptic plasticity
throughout life, cell migration, and the removal of misfolded proteins [3,41–43]. However,
when the complement system in the CNS becomes dysregulated, it can be a contributor
to neurological, neurodegenerative, and psychiatric diseases [16]. Studies have shown
that complement proteins, complement control proteins, and receptors are upregulated in
immunohistopathological analysis of post-mortem human brain tissue and cerebrospinal
fluid (CSF) [3,16].
The Complement System
Depending on the target ligand, the complement system can be activated by three
pathways: classical, alternative, and lectin [15,16,44]. All three pathways share the common
central component of the complement system C3, and downstream of C3 results in the
formation of the MAC [15] (Figure 2). However, the pathways differ according to the ligand
they can bind to [15,44].
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Figure 2. The complement system consists of more than 40 soluble or membrane-bound proteins, and is activated via
classical, lectin or alternative pathway. The classical pathway is activated by Aβ andp-tau. Apoptotic cells and antigen-
antibody complexes interact with C1q (complexed with C1r2 and C1s2). C1s then cleaves C4 and C2 and ultimately leading
to the formation of C3 convertase C4b2b. The lectin pathway is activated by mannan-binding lectin (MBL) and ficolin, which
then recruits MASPs (MBL-associated serine proteases) to cleave C2 and C4, yielding C3 convertase, C4b2b. The alternative
pathway is an amplification loop and is also initi ted by hydrolysis of C3 to C3(H2O) which le ds to the formation of
C3 convertase, C3bBb. All three pathways lead to formation of C5 convertase (classical and lectin: C4b2b3b; alternative:
C3bBb3b) generating C5b which binds to C6, C7, C8, and C9 to form a cell lysi g membrane attack complex (MAC). Some
of the mechanisms of complement activation in AD are shown in the blue boxes.
The cl ssical pathway of the complement system is activated when the C1 complex
(C1q, C1r2, and C1 2) binds via C1q, the first subcomponent of the classical pathway,
to a target ligand such as the Fc region of com lement fixing IgG nd IgM [15,40,45].
Furthermore, C1q can bind to aggregated Aβ as well as hyperphosphorylated tau [46–48]
(Table 1).
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The C1 complex is composed of C1q (Figure 2), a charge pattern recognition molecule,
and a tetramer of serine proteases C1r2 and C1s2 [15,40,44,45]. C1q serves as a molecular
scaffold to C1r2 and C1s2; binding of C1q to a target ligand autoactivates C1r, which
subsequently cleaves and activates C1s [44]. The activated C1s then goes on to cleave C4 to
generate C4a and C4b which are an anaphylatoxin and opsonin, respectively [40,49]. C4b
then recruits C2 [40]. C1s then cleaves C2 in to C2a and C2b [40]. The cleaved products
C4b and C2b form C4b2b, a proconvertase complex [40,49,50]. The proconvertase complex
is cleaved by C1s which results in C3 convertase, C4b2a [40,51]. C3 convertase cleaves
multiple C3 proteins in to C3a and C3b [38,40]. C3b serves two functions, the first being
an opsonin where it will covalently attach to the surface of a pathogens and drives the
amplification of the complement alternative pathway, which results in opsonisation and
phagocytosis of the tagged pathogen [38,40].The second function is where C3b leads to
the downstream activation of the terminal pathway forming the MAC [38,40]. This is
performed by C3b associating with C4b2b which results in the formation of C4b2b3b,
known as C5 convertase of the classical pathway [40]. C5 convertase then cleaves C5 into
C5a (an anaphylatoxin that also acts as a chemoattractant) and C5b, the latter facilitates the
formation of the C5b, C6, C7, C8, and C9 complex (C5b-9), known as the MAC [37,38,40,52].
The MAC can then bind to the cell membrane and cause cell lysis [15].
The alternative pathway of the complement system is an essential amplification
loop and the pathway is regulated by several control proteins, factors B, D, H, I, and
properdin [53] (Figure 2). C3b molecules generated from any of the three pathways can
covalently attach to the cell surface of a pathogen. C3b associates with factor B which
results in the formation of C3bB, a Mg2+ dependent proconvertase complex [53]. Factor B
is then cleaved by factor D to form Bb and Ba [54]. This results in the formation of C3bBb,
which is the C3 convertase of the alternative pathway [53,54]. C3bBb cleaves C3 to C3a, an
anaphylatoxin (which can also act as a chemoattractant) and C3b, of which C3b forms the
alternative pathway amplification loop forming a new C3bBb complex each time [53,54].
Furthermore, the alternative pathway is continuously initiated by the slow hydrolysis
of C3 to C3(H2O) [53]. This is achieved by the hydrolysis of the internal thioester bond
within C3 by water in plasma [53]. This is known as the “tick over theory” which was
proposed by Lachmann et al. [53,55]. C3(H2O) has also been described as “C3b like”
molecule by Pagburn et al. [53,56]. The hydrolysis of C3 to C3(H2O) causes a structural
change which allows the binding of Factor B (FB) [56]. This C3(H2O) and FB-bound
complex is cleaved by a protease, Factor D (FD), resulting in the formation of Ba and
Bb [54]. The larger Bb fragment remains associated with the C3(H2O) complex resulting
in the formation of C3(H2O)Bb, a C3 convertase protease complex [54]. This complex can
cleave additional C3 molecules through its serine protease domain which results in the
formation of C3a and C3b [54]. The C3b molecule can function as an opsonin or bind
to C3 convertase (C3bBb), resulting in the formation of C5 convertase (C3bBb3b) of the
alternative pathway, followed by formation of the MAC [54].
Both types of C3 convertases generated by the alternative pathway have a very short
half-life, and therefore, require stabilisation by a binding partner called properdin [57]
(Figure 2). When properdin binds to C3bBb, it can increase its stability/half-life by up
to 10-fold; but this is less for C3(H2O)Bb [57,58]. Additionally, properdin may be able to
act as a pattern recognition molecule which can bind to microorganisms and initiate the
alternative pathway [59,60]. This can potentially explain properdin colocalising with Aβ
plaques and other complement proteins in an AD mouse model, and more importantly,
C1q−/− mice AD [61].
The alternative pathway can be regulated by control proteins such as Factor H (FH)
and factor I (FI) [15,16,62]. FH is an essential soluble regulator of the alternative pathway
where it competes with FB for binding to C3b, thus prevents the formation of C3 convertase
(C3bBb) by promoting the disassociation of Bb from C3bBb. FH is also known as the
decay accelerating factor of the alternative pathway which can downregulate activity of
the alternative pathway [63]. The stabilisation of the alternative pathway C3 convertases
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though properdin distorts the binding site of FH [15,16,62,64]. FH also has the ability to act
as a cofactor for FI which results in the irreversible degradation of C3b to iC3b (inactivated
C3b) which is not able to bind to FB [15,16,62,64]. FH is composed of 20 complement
control proteins (CCPs): CCPs 1–4 allow the functional activity of FH which include decay
acceleration by disassociating Bb from C3bBb, cofactor activity for FI and binding to C3b
in an extended configuration [65]. Additionally, the FH affinity is increased through gly-
cosaminoglycans and sialic acid, both expressed on self-cells, which may explain how FH
can discriminate between self and nonself cells and prevent self-damage by the comple-
ment system [65]. The affinity of FH for C3b increases via CCP sites 1–4, 7–15 and 19–20;
SNPs within these sites are considered to contribute to neuroinflammation and a potential
role in AD pathophysiology [15,16,65].
The lectin pathway of the complement system is activated through pattern recognition
molecules such as mannane-binding lectin (MBL) and ficolins, which bind to oligosaccha-
rides on the surface of pathogens [66–68]. These pattern recognition molecules have an
N-terminal collagenous region similar to C1q, but the C-terminal region differs as they con-
tain C-type lectin domains [66–68]. Once activated, associated enzymes mannan-binding
lectin serine protease 1 (MASP1) activates MASP2 which goes on to cleave C2 and C4 in to
C2a, C2b, C4a and C4b; of which C2a and C4b form C3 convertase, C4b2a [66–68]. This
pathway can then lead to the eventual formation of the MAC.
Table 1. Functions of complement system in the central nervous system.
Functions of Complement System Role Mechanism Reference
Neuroprotection
Neurogenesis
Increased complement receptor activation in the
development of cerebellar neurons in animal
models.
[67]
Disrupting C3aR signalling in mice models
impairs neurogenesis. [68]
CR2 is a negative regulator of neurogenesis. [67,68]
Synaptic pruning
C1q−/− mice exhibit increased synaptic
connections resulting in epilepsy, indicating an
essential role in synaptic pruning.
[69,70]
Synaptic plasticity C1q−/− mice show weak dendrites and spines. [69]
Neuroinflammation
Binding with Aβ Activation of classical pathway. [42,43,71]
Binding with Tau
protein




Neuronal death due to release of
proinflammatory cytokines. [15,29,30,73]
C1q released by microglia can induce A1
astrocytes. [73]




Neuronal death due to release of
pro-inflammatory cytokines. [73,77]
Neurotoxic A1 astrocytes can activate the





Increased release of C3 via activation of NF-κB
pathway resulting in microglia activation and
release of pro-inflammatory cytokines.
[81,82]
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3. Complement System and Alzheimer’s Disease
3.1. Role of the Complement System in Central Nervous System Physiology
The CNS was thought to be an immune privileged system due to the BBB [16]. How-
ever, it is now known that complement components can be produced within the CNS by
astrocytes, microglia, and neurons [16,69,70]. The complement system can be neuroprotec-
tive as well as neurotoxic, dependent on initiating targets and the level of activation [16]
(Table 1).
The complement system has been demonstrated to have a role in neurogenesis. This
was indicated in an in vivo study by Bénard et al., who identified an increased expression
of C3aR and C5aR in 12-day old rat cerebellar neurons, suggesting these receptors were
involved in neurogenesis [16,83] (Table 1). This was supported by Raphpeymai et al. who
demonstrated an impairment of neurogenesis in C3−/− and C3aR−/− mice, suggesting an
involvement of C3aR signalling in neurogenesis [16,71]. Complement receptor 2 (CR2) also
has a role in neurogenesis in adult neural progenitor cells; CR2−/− mice show increased
hippocampal neurogenesis, thus CR2 seems to be a negative regulator of hippocampal
neurogenesis [16,71,83] (Table 1).
C1q has been shown to play a role in synaptic pruning and synaptic plasticity [42].
C1q−/− mice show an increase in synaptic connections; increased synaptic connections in
C1q−/− mice can result in epilepsy [42,72,84]. C1q−/− mice also show increased synaptic
plasticity in the regions of the brain such as the hippocampus, which are associated with
neurodegenerative diseases such as dementias [42,72,84] (Table 1).
3.2. The Specific Role of the Complement System in Alzheimer’s Disease
The very important role of the complement system in AD pathophysiology is sup-
ported by neuropathology observed in vitro and in vivo. Studies have revealed that comple-
ment protein expression and complement activation lead to neuroinflammation, neuronal
and synapse loss and subsequent neurodegeneration which is seen in AD patients. Com-
plement proteins have been colocalised with Aβ plaques. A post-mortem study conducted
by Rogers et al. (1992), who analysed AD patients brain tissues, showed elevated levels
of C1q, C3, and C4 co-localisation with Aβ plaques compared with control samples [47]
(Table 1). Another study observed elevated levels of C3 and C4 mRNA in the temporal
cortex of AD brains [85]. A study by McGeer et al. (1989) identified an abundance of
positive immunohistochemical staining of C1q, C3, and C4 and their colocalization with
Aβ plaques and NFTs in AD brain tissue [52]. Specific staining for complement activation
products such as C3b and the products of the terminal MAC (C5b-C9) in AD brain tissues
has also been reported, indicating that that MAC can potentially cause neuronal loss and
neurodegeneration in AD [85].
It is likely that the complement dysfunction may be contributing to neuroinflam-
mation and subsequent neurodegeneration decades before clinical symptoms manifest
in an individual with AD; this can be due to Aβ accumulation which overwhelms the
complement system and drives the pathology of AD. In vitro studies have demonstrated
that Aβ1-42 can directly activate the classical pathway by binding to C1q via its globular
domain [86]. C1q can also bind to tau via the C1qA collagen domain and activate the
classical pathway [87]. Thus, complement activation due to the binding of C1q to Aβ and
tau can potentially contribute to neuroinflammation and neurodegeneration in AD.
Animal models have allowed reproduction of the hallmarks of AD. Studies on C3
gene-deficient mice (C3−/−) that had a nerve injury showed a faster recovery compared
with WT mice, indicating the complement system is involved in synapse removal and
hinders recovery [88]. Another study examined the role of the complement on synapses in
ageing mice and observed that C3−/− mice had better learning and memory in regions
of the brain such as the hippocampus compared with their respective aged WT mice,
suggesting that C3 or downstream complement components play a role in hampering
synapses as a part of the aging process [89]. However, other studies have suggested that
the complement system is essential for synaptic pruning [72,84] (Table 1). The complement
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system in a normal brain may aid in synaptic plasticity throughout life, but in the later
stages of life, insults and accumulation of Aβ and NFTs can overactivate the complement
or cause its dysfunction and fail to clear the hallmarks of AD 3.
An in vivo study used PS1/APP mouse model, a cross between transgenic mice
carrying a mutation in the APP (APPK670N,M671L) which exhibits increased levels of Aβ
deposition in the hippocampus and cerebral cortex, and mutant PS1 transgenic mice which
have no pathological changes but show mildly elevated levels of Aβ1-42 and Aβ1-43
peptides [90–92]. The resulting PS1/APP transgenic mice showed an accelerated Aβ
accumulation and deposition providing a useful amyloid phenotype of AD [92,93]. The
study reported that C1q co-localised with Aβ plaques and activated microglia [92]. This was
supported by another study which showed that C1q bound to Aβ and caused phagocytosis
via microglia [94]. The role of C1q was examined further by Fonseca et al. (2004), who
crossed AD mice model Tg2576 mice (APP mutation) with C1q−/− mice, giving rise to
APPQ−/− mice which exhibited AD pathology but lacked C1q, and these mice were
compared with APP mice [90,93,95,96]. At older ages, both types of mice developed
Aβ. However, activated forms of microglia were significantly lower in APPQ−/− mice
compared with Tg2576 mice which indicated that C1q can have a potential detrimental
effect on neurons by activating both microglia and the classical pathway [95].
Hong et al. (2016) found that human APP (hAPP) (J20) transgenic mice, a mouse
model which overexpresses hAPP with mutations linked to familial AD (Swedish and
Indiana mutations) yielding vast amount of Aβ plaques at young age, showed an increase
in C1q from approximately 1 month of age compared with its WT mice, and this was prior
to the formation of Aβ plaques. This posed the question if C1q increase is dependent
on soluble Aβ levels [97–99]. When the J20 mice were administered “compound E”, a
γ-secretase inhibitor which rapidly decreased Aβ levels, there was a marked reduction in
C1q levels, implying that C1q levels and activation of the complement can be dependent
on Aβ levels [97]. When WT mice were injected with Aβ oligomers, there was a loss of
synaptic density within 72 h [97]. However, this was not the case in C1q−/− mice which
indicated that the inhibition (absence) of the classical pathway led to reduced neurotoxic
effects of Aβ [97]. Thus, C1q-mediated classical pathway activation is increased by Aβ
peptides that triggers the downstream pathway leading to neurodegeneration [97]. A
recent study examined the relationship between synapse dysfunction and synapse loss
in conjunction with C1q [100]. The study used APP/PS1 mice and control WT mice, both
types of mice had fluorescent C1q tags [100]. The study observed a decline in mitochondrial
function and changes in the septin protein structure which aids in synaptic transmission
in the area where C1q was tagged, suggesting that the synapse loss was mediated by the
complement system [100].
Shi et al. (2017) examined the role the complement on synapses and cognition in
C3−/− AD mice (APP/PS1-C3 KO) [101]. The mice were obtained by breeding C3−/−
mice with APP/PS1 mice [101–103]. The APP/PS1- C3−/− mice had an abundance of Aβ
in late-stage AD and they performed significantly better in cognitive tasks compared with
APP/PS1 mice [101]. Additionally, there was a marked reduction in pro-inflammatory
cytokines such as IL-12, TNFα and Interferon gamma (IFN-γ), and decreased activation of
microglia (as evident from microglial immunoreactive markers CD68 and Iba-1) despite
the abundance of Aβ, suggesting that early complement components in the presence of
Aβ can mediate the downstream activation of the complement system which can result in
gliosis, neuroinflammation and neurodegeneration [101].
4. Role of Glial Cells in AD and the Complement System
Astrocytes constitute approximately 30% of the cells in the CNS; they can morpho-
logically be found in two forms, protoplasmic (in grey matter) and fibrous (in white mat-
ter) [16,104]. Astrocytes contribute to the BBB via their astrocytic end-feet, which line the
surface of the brain and form a covering around the cerebral vessels and synapses [105,106].
Astrocytes also have a role in neuronal development and synaptogenesis, providing
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metabolic support to synapses [104,105]. Insults to the CNS causes astrocytes to change
their morphology to become reactive astrocytes which exhibit hypertrophy of their pro-
cesses and upregulate the release of glial fibrillary acidic protein (GFAP) and S100B; all
of which are seen in AD brain tissue analysis [16,77]. Studies on AD human brains have
identified reactive astrocytes in close proximity to Aβ plaques, and astrocytes containing
Aβ plaques have also been stained positive; this may indicate a potential role of astrocytes
in the clearance of Aβ in the early stages of AD [107,108]. Animal model studies have
demonstrated that astrocytes migrate to Aβ via chemokines such as monocyte chemoat-
tractant protein-1 (MCP-1), present in Aβ plaques and that astrocytes bind to and degrade
Aβ [73]. Injection of Aβ oligomers induced a strong activation of astrocytes via the nuclear
factor-kappa B (NF-κB) leading to the production of pro-inflammatory cytokines IL-1β
and TNFα, surrounding injection sites and in close proximity to blood vessels which can
draw in further glial cells, contributing to neuroinflammation [78] (Table 1). Furthermore,
astrocytes have the ability to phagocytose Aβ [79,80]. Astrocytes exist in two reactivity
states: A1 and A2 [81]. A2 astrocytes are neuroprotective as they perform homeostatic
functions that helps restore activity of neurons and synapses after insults, whereas A1
astrocytes fail to perform this and convert to a neurotoxic form [81,82]. These neurotoxic
A1 astrocytes can significantly increase activation of the complement classical pathway [81]
(Table 1). Additionally, pro-inflammatory cytokines such as IL-1 and TNFα, and com-
plement components including C1q, which are released by microglia, can also induce
A1 astrocyte phenotype [81]. Extracellular tau aggregates can bind to astrocytes, get in-
ternalised via an integrin αV/β1 receptor; the integrin signalling pathway causes NF-κB
activation leading to the release of several pro-inflammatory cytokines and chemokines
that converts astrocytes to an A1-like neurotoxic state [82,109,110]. The NF-κB pathway is
also implicated by another study where exposure to Aβ activates this pathway and causes
an increased release of C3 which can bind to neuronal and microglia C3aR, resulting in
microglia activation, and release of proinflammatory cytokines [111,112]. C3 transcripts
are also known to be upregulated in A1 astrocytes [81] (Table 1).
Post-mortem examination of AD brain tissues revealed an abundance of A1 astrocytes
which also stained positive for C3 in brain regions affected by AD [81]. Furthermore, C1q
was found to induce the A1 phenotype of astrocytes in vivo [81]. Following traumatic nerve
crush injuries, C1q−/− mice showed a significant decrease in A1 astrocytes in comparison
with WT controls [81], suggesting C1q influence on A1 astrocyte phenotype
Microglia are the resident immune cells of the CNS and constitute approximately
10–15% of the total glial cell population in the adult human brain (Figure 3) [113]. Mi-
croglia play an essential role in immune surveillance in the CNS; they have long-ramified
processes which they use to survey the microenvironment for cellular debris, pathogens,
and misfolded proteins, and provide tropic support to the brain [114,115]. Other functions
of microglia include neurogenesis, apoptosis, synaptic plasticity, and synaptic pruning in
conjunction with the complement system, particularly C1q (Figure 3) [116,117].
It is generally accepted that microglia can exist in two predominant phenotypes
upon activation: M1 and M2 [118]. The classical M1 phenotype is associated with an
upregulation of pro-inflammatory cytokines such as IL-1, IL-6, TNFα and C1q which can
result in a neurotoxic environment as they can activate A1 astrocytes, forming a vicious
pro-inflammatory positive feedback loop [81,104,118]. This also correlates with studies
involving TBI and subsequent neuroinflammation [119]. The alternative M2 phenotype
is associated with secretion of anti-inflammatory cytokines such as IL-4, IL-9, IL-10 and
transforming growth factor beta (TGF-β) [81,104,118] (Table 1).
Microglia can perform immune surveillance in the brains via several innate immune
pattern recognition receptors (PRRs) including scavenger receptors (such as CD36), Toll-like
receptors (TLRs), receptors for advanced glycosylation end products (RAGE) and other
receptors such as CD14 and CD47 [120–122]. PRRs can responds to insults via damage asso-
ciated molecular patterns (DAMPs) and pathogen associated molecular patterns (PAMPs),
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which have the ability to recognise cellular debris, pathogens and misfolded proteins such
as Aβ and induce a microglial response [16].
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Aβ is also able to bind TLR-2, 4, 6, and 9 resulting in microglial activation
the subs quent rele e of pro-inflammatory cytokines d chemokines which recruit
more microglia t the site [123,124]. ntibody blockin of TLR-2 r sults in reduced pro-
inflammatory ytokine production [124]. I TLR-2−/− mice, Aβ peptides were not able to
induce a pro-inflammatory response [124].
Balducci et al. examined the role of Aβ on TLR-4 and its effects on microglial activation
in mice [125]. When mice were provided a cerebroventricular injection of Aβ peptides,
this activated microglia and a marked increase in pro-inflammatory cytokines such as
TNFα [125]. The study compared the effects of Aβ on TLR-4−/− mice and control WT
mice who were injected with Aβ [125]. Aβ had a devastating impact on memory in
WT mice, while no changes in memory were found in TLR-4−/− mice, implicating TLR-
4 in microglial activation and neuroinflammation [125]. In another study, TLR-4 and
TLR-6 were implicated along with CD36, in the inductionof microglia in the presence of
Aβ [123]. A study Scholtzova et al. (2017) used a TLR-9 agonist: class B cytosine–phosphate–
guanine (CpG) oligodeoxynucleotides (ODNs) in a triple transgenic mice model (Tg-SwD),
which had significant cerebral amyloid angiopathy (CAA) and observed that CpG ODN
reduced CAA and improved cognition, implicating TLR-9 in microglial activation [126].
Studies have also demonstrated that Aβ can activate microglia via the CD36, CD14, and
CD47 receptors [120]. The release of certain types of pro-inflammatory cytokines such
as TNFα upon Aβ binding can result in an increase in phagocytic activity of microglia
which can further exacerbate neuroinflammatory events by activating A1 astrocytes and
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via C1q which can bind to Aβ plaques, resulting in synapse elimination and eventual
neurodegeneration [74].
Chemokines, and anaphylatoxins such as C3a and C5a, which have chemoattractant
properties, are also implicated in AD. One study examined the chemokine receptor CX3CR1
which is expressed on microglia and allows Fractalkine (CX3CL1) binding which recruits
more microglia to sites of neuroinflammation, e.g., Aβ plaques in AD [127]. Heterozygous
PS1/APP-CX3CR1+/− mice, compared with age-matched PS1/APP mice, had a significant
reduction in Aβ plaques in the brain compared with the control mice, and levels of Aβ
degrading enzymes such as insulin-degrading enzyme and matrix metalloproteinase 9
which are produced by neurons, were also significantly reduced, suggesting a potential
therapeutic target to promote Aβ clearance [127].
Several in vivo and in vitro studies have been conducted to determine how comple-
ment proteins are produced in the brain. Early in vitro studies of glial cell lines suggested
the possibility of the synthesis and secretion of complement proteins [128,129]. The pres-
ence of complement receptors on microglia for C1q, C3a, and C5a, was also noted which
could enhance microglial phagocytosis [130] (Table 1). The complement system and mi-
croglia can exist in harmony in the absence of insults in a neuroprotective manner. CR3−/−
mice have a defect in microglia-mediated synapse elimination compared with controls.
This highlighted the important role of microglia and the complement in normal brain
development [75]. However, in AD, the activation of the complement system and microglia
can be detrimental to neurons. This was demonstrated in an in vivo study where Aβ was
added to glial neuronal cultures, resulting in CR3 mediated neuronal loss. However, this
was prevented by blocking CD11b, a component of CR3, possibly showing a therapeutic
target for CR3 [76].
C1q has also been shown to be detrimental to neurons in the presence of Aβ. Microglia
are the main source of C1q in the adult brain and its levels increase with age [131]. C1q can
bind to Aβ and trigger the classical pathway; C1q can also bind to neuronal insult sites,
resulting in local apoptosis and pro-inflammatory cytokine release [132]. In response to
this, microglia can take on the M1 phenotype and become activated and express receptors
for C3a and C5a which further increases local inflammation. The sites which are C1q
tagged can be opsonised by C3b and then phagocytosed by the M1 microglia; this has
been demonstrated in animal model studies [42]. Some recent studies have determined
a role of tau in microglial activation. In a tau mouse model upon administration of a
C1q antibody, microglia induced synapse loss was prevented and synaptic density was
recovered [133,134]. Additionally, the deletion/absence of C3aR on microglia led to the
reduction in neuroinflammation and thus neurodegeneration [133,134].
5. Therapeutics
Several clinical trials have taken place and are underway to find a cure for AD (Table 2).
Some of the most promising trials for AD were based on the Aβ cascade hypothesis. Aβ
targeting monoclonal antibodies (mAbs) such as solanezumab progressed to phase III
clinical trials [18,135]. Solanezumab was able to bind to soluble Aβ and this was achieved
in AD patients where plasma concentrations of Aβ decreased by approximately 90% but
cognition still deteriorated [18,135]. Other mAbs such as gantenerumab and crenezumab
succeeded in targeting Aβ but failed to prevent cognitive decline [18,136]. Aducanumab
is another mAb which was shown to target neurotoxic Aβ peptides and progressed to
phase III studies, named EMERGE and ENGAGE [137]. The EMERGE study used higher
doses compared with the ENGAGE study and thus showed a mark reduction in cognitive
decline, reduction in Aβ plaques and NFTs identified from positron emission tomography
(PET) scans and p-tau reduction was identified from CSF analysis [137]. The ENGAGE
study only yielded positive results such as the EMERGE study, in individuals treated with
a higher dose for a longer period of time [137]. However, despite positive results, the trials
were stopped by the sponsor due to efficacy related issues between both studies [137].
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Table 2. Summary of the clinical trials for treating AD.
Target Drug Additional Trial Information Reference
Aβ
Solanezumab
Solanezumab, a human monoclonal antibody directed against soluble Aβ.
A double blind, placebo-controlled phase 3 trial in individuals with mild AD
which was defined by a mini mental state examination score of 20-26 and Aβ
confirmation via a positron emission tomography (PET) scan or Aβ1-42 CSF
analysis.
Approximate 90% reduction in soluble Aβ but cognition continued to decline.
[18,132]
Gantenerumab
Gantenerumab, a human monoclonal antibody directed against Aβ aggregates.
A double blind, placebo-controlled phase 3 trial in individuals with AD selected
via several neuropsychological analysis, MRI, CSF analysis and PET scan.




Crenezumab is a monoclonal antibody which can bind to Aβ fibrils, monomers
and oligomers.
Phase 3 trials terminated early as cognition continued to decline.
[18]
Aducanumab
Aducanumab, a monoclonal antibody that targets Aβ.
Study showed high affinity for neurotoxic Aβ.
Phase 3 trials named EMERGE and ENGAGE.
EMERGE study identified a reduction in cognitive decline, Aβ plaques, NFTs
and p-tau.
Recently approved by U.S. Food and Drug Administration (FDA) for patients
with early AD and Aβ plaque build.
[134]
Tau TRx0237
TRx0237, a low dose leuco-methylthioninium bis(hydromethanesulphonate)
(LMTM) is a tau aggregation inhibitor.
Currently in phase 3 trials in patients with mild AD.
So far results have shown a reduction in general brain atrophy compared with
control patients.
[136]
A more promising approach may be to target neurotoxic Aβ peptides which have been
post-translationally modified with a pyroglutamate at the N-terminus (pGlu3, pE3) [138].
Hettmann et al. generated an anti-pGlu3-Aβ antibody, called PBD-C06, which was shown
in vitro to strongly bind to pGlu3-Aβ peptides [138]. The advantage of this antibody is
that it will not react with APP nor with other non-pathological Aβ peptides in the brain
or periphery, thus it has minimal toxic effects [138]. Furthermore, the peptide is designed
by making a K322A substitution on the Fc region which essentially keeps the Fc binding
integrity but inhibits the C1q binding; this can prevent activation of the complement
system and thus prevent a microglial response in individuals with AD [138]. It has been
difficult to identify tau targets as they are an essential component of microtubules in the
CNS. However, studies are being undertaken to identify drugs which can fall into these
categories: tau kinase inhibitors, tau aggregation inhibitors, microtubule stabilises and
immunotherapies [18]. Tau aggregation inhibitors such as TRx0237 are currently in phase
III clinical trials and so far in 9 months of treatment in AD patients, general atrophy of the
brain slowed down compared with control patients [18,139] (Table 2).
From the information above, it is known that TNFα, a proinflammatory cytokine,
can result in the formation of M1 microglia and release of C1q. Adalimumab is a mAb
against TNFα and has been studied via in vivo animal models [140]. Park et al. (2019)
examined if adalimumab can improve cognition and reduce AD pathology in an Aβ
injected mouse model of AD [140]. The Aβ injected mice were treated with the mAb and
significant improvement in memory was noticed in comparison with Aβ alone injected
control mice [140]. In the Aβ injected mice being treated with the mAb, there was also a
reduction in BACE1 as well as Aβ plaques [140]. Adalimumab is a biological drug which is
licensed to be used in many inflammatory conditions such as rheumatoid arthritis, psoriatic
arthritis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis [2]. Thus, it can be
possible to conduct a prospective study on individuals who are receiving adalimumab if
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any of them go on to develop AD. It can also be worthwhile investigating if AD patients
with above-mentioned inflammatory diseases who are being treated with adalimumab
show improvement in their cognition
Complement inhibition can potentially help to slow down the progression of AD.
Complement inhibition was investigated in a study by Lee et al. (2017), who used PMX205
as a C5aR antagonist in hSOD1G93A mice which are a model of amyotrophic lateral sclerosis
(ALS) [141]. The study recognized that orally administered PMX205 managed to enter the
CNS in a pharmacologically active concentration and improved grip strength in those mice
thus slowing the progression of the disease as well as increasing survival. [141].
Inhibition of C1q in animal models has shown an improvement in cognition and
reduction in AD pathology, as mentioned above. Many have pondered if an anti-C1q drugs
can be a therapeutic for AD or other CNS conditions. However, there is a potential of
increased susceptibility to infection and immune complex deposition in various organs
following C1q deficiency [2]. Furthermore, high doses would also have to be given to
penetrate the BBB to ensure a pharmacologically active concentration [142].
6. Conclusions and Future Perspectives
Current evidence on the pathophysiology of AD indicates that the complement system
plays both a neuroprotective and neuroinflammatory role. During the early stages of AD
when clinical symptoms have not manifested, the complement system can succeed in
clearing Aβ in conjunction with glial cells. However, when Aβ starts to accumulate and Aβ
plaques develop, the consequent chronic inflammation is detrimental. Glial cells acquire
their neurotoxic phenotypes and release C1q which can directly bind to Aβ at synapses
and cause a release of pro-inflammatory cytokines. Some of these cytokines have the ability
to further increase the phagocytic capability of microglia. Microglia can then engulf the
synapses which results in early synaptic loss and then gradual neurodegeneration as seen
in AD. This pro-inflammatory cascade can function as a positive loop and lead to more
neuroinflammation and neurodegeneration.
Complement proteins and regulators must be further explored. Lee et al. (2017)
were successful in using a C5aR antagonist which entered the CNS in a pharmacologically
active concentration and slowed the progression of ALS in mice [141]. C1q can pose
as a prime target to disrupt the complement system and prevent neuroinflammation
and neurodegeneration. Another complement target can be C3aR as it is a key receptor
expressed on both neurons and microglia. This would essentially aid in the reduction in
the phagocytic activity of microglia and potentially reduce the release of pro-inflammatory
cytokines. Another point of the complement system which can be investigated is C3
convertase of the classical pathway, C4b2a. Such regulation of the pathway can prevent the
cleavage of C3 to C3b; thereby, preventing the downstream pathway of the complement
system and stopping cell lysis and reducing synaptic loss and neurodegeneration.
Furthermore, it may be worthwhile looking into potential brain complement specific
biomarkers which can indicate if an individual has an increased susceptibility to develop
AD in the future. Additionally, it is worth investigating if any individuals who has an
inflammatory condition and have AD benefits in terms of cognition following biological
mAb treatment. Clinical trials (Table 2) using mAb targeting Aβ have not showed much
desired results in terms of improving cognition or slowing down the progression of AD.
One exception is Aducanumab which was recently approved by the FDA for use in individ-
uals with mild AD and a high Aβ plaque load. It may also be worthwhile exploring other
potential therapeutic targets for AD, such as p-tau and complement targeted therapies.
Promising results have been seen in the trial of TRx0237, a tau aggregation inhibitor which
opens a door to potentially exploring other tau targets such as p-tau epitopes. Complement
targeted therapies are unlikely to reverse AD, unless picked up very early on, but they
can potentially modify or slow the progression of the disease by protecting the brain from
chronic neuroinflammation before symptoms begin to manifest. Complement targeted
therapies will most likely face the same challenges as mAb such as penetrating the BBB
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without causing any complications in other systems such as circulatory, respiratory, etc.
More research needs to be carried out on mechanisms in prevention or regulation of mi-
croglia in acquiring the neurotoxic M1 phenotype by potentially blocking C3aR and C5aR.
There is a potential to explore the relationship of C1q and Aβ.
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